Your browser doesn't support javascript.
loading
The 2023 ACR/EULAR antiphospholipid syndrome classification criteria identify patients at high risk of complications.
Castillo-Martínez, Diana; Mora-Ramírez, Mauricio; Molina-Sánchez, Raúl; Amezcua-Guerra, Luis M.
Afiliação
  • Castillo-Martínez D; Dermatology, Hospital General de Zona 32, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
  • Mora-Ramírez M; Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
  • Molina-Sánchez R; Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
  • Amezcua-Guerra LM; Immunology, Instituto Nacional de Cardiología Ignacio Chávez, Juan Badiano 1, Sección XVI, Tlalpan, 14080, Mexico City, Mexico. lmamezcuag@gmail.com.
Clin Rheumatol ; 43(11): 3373-3377, 2024 Nov.
Article em En | MEDLINE | ID: mdl-39294500
ABSTRACT

OBJECTIVES:

This study aims to evaluate the utility of the 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria in identifying primary APS patients at high risk of complications.

METHODS:

In this single-center study, primary APS patients were classified according to both the revised Sapporo criteria and the 2023 ACR/EULAR criteria. The risk of complications was assessed using the adjusted Global Antiphospholipid Syndrome Score (aGAPSS).

RESULTS:

Forty-five patients (73% females, median age 49 years) were included. Thirty-six patients met the 2023 ACR/EULAR criteria, all of whom also fulfilled the revised Sapporo criteria. Additionally, four out of nine patients not meeting the 2023 ACR/EULAR criteria satisfied the revised Sapporo criteria. Agreement rate between the two classification criteria was 91%, with a Cohen's kappa index of 0.66. Patients meeting the 2023 ACR/EULAR criteria had significantly higher aGAPSS scores compared to those who did not (13, 8-13 vs. 3, 0-5; p = 0.005). Furthermore, 55% of patients meeting the 2023 ACR/EULAR criteria were categorized as high risk based on aGAPSS scores, while those not meeting the criteria were predominantly categorized as low risk (77%). Interestingly, patients not meeting the 2023 ACR/EULAR criteria but fulfilling the revised Sapporo criteria had significantly higher aGAPSS scores compared to those not meeting either set of criteria (7, 5-13 vs. 0, 0-1.5; p = 0.015).

CONCLUSION:

The 2023 ACR/EULAR criteria effectively identify primary APS patients at increased risk of complications, as indicated by the aGAPSS score. Key Points • Identifying primary APS patients at high risk of complications remains a significant challenge. • The 2023 ACR/EULAR criteria show a correlation with the aGAPSS score, exhibiting the highest correlation with laboratory domains and minimal correlation with clinical domains. • The 2023 ACR/EULAR classification criteria are effective in identifying primary APS patients at high risk of complications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: México País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome Antifosfolipídica Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Rheumatol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: México País de publicação: Alemanha